Is Hydroxychloroquine with Azithromycin a Good Combination in COVID-19 Compared to Hydroxychloroquine Alone from Cardiac Perspective? A Systematic Review and Meta-Analysis

  • Pravash Budhathoki Department of Emergency Medicine, Dr Iwamura Memorial Hospital, Bhaktapur-44800, Nepal
  • Dhan Bahadur Shrestha Department of Emergency Medicine, Mangalbare Hospital, Morang-56600, Nepal
  • Sitaram Khadka Department of Pharmacy, Shree Birendra Hospital; Nepalese Army Institute of Health Sciences, Kathmandu-44600, Nepal
  • Era Rawal Department of Emergency Medicine, Kathmandu Medical College, Kathmandu-44600, Nepal

Abstract

Background: The global spread of COVID-19 and the lack of definite treatment have caused an alarming crisis in the world. We aimed to evaluate the outcome and potential harmful cardiac effects of hydroxychloroquine and azithromycin compared to hydroxychloroquine alone for COVID-19 treatment.
Methods: PubMed, Medline, Google Scholar, Cochrane Library, clinicaltrials.gov, and World Health Organization clinical trial registry were searched using appropriate keywords and identified six studies using PRISMA guidelines. The quantitative synthesis was performed using fixed or random effects for the pooling of studies based on heterogeneities.
Results: The risk of mortality (RR=1.16; CI: 0.92-1.46) and adverse cardiac events (OR=1.06; CI: 0.82-1.37) demonstrated a small increment though of no significance. There were no increased odds of mechanical ventilation (OR=0.84; CI: 0.33-2.15) and significant QTc prolongation (OR=0.84, CI: 0.59-1.21). Neither the critical QTc threshold (OR=1.92, CI: 0.81-4.56) nor absolute ?QTc ?60ms (OR=1.95, CI:0.55-6.96) increased to the level of statistical significance among hydroxychloroquine and azithromycin arm compared to hydroxychloroquine alone, but the slightly increased odds need to be considered in clinical practice.
Conclusions: The combination of hydroxychloroquine and azithromycin leads to small increased odds of mortality and cardiac events compared to hydroxychloroquine alone. The use of hydroxychloroquine and azithromycin led to increased odds of QT prolongation, although not statistically significant.
Keywords: COVID-19; COVID-19 drug treatment; hydroxychloroquine; macrolides; severe acute respiratory syndrome coronavirus 2 

Published
2021-04-23
How to Cite
BudhathokiP., ShresthaD. B., KhadkaS., & RawalE. (2021). Is Hydroxychloroquine with Azithromycin a Good Combination in COVID-19 Compared to Hydroxychloroquine Alone from Cardiac Perspective? A Systematic Review and Meta-Analysis. Journal of Nepal Health Research Council, 19(1), 1-9. https://doi.org/10.33314/jnhrc.v19i1.3270